Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450...
Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes : A combined cocktail trial
About this item
Full title
Author / Creator
Publisher
Heidelberg: Springer
Journal title
Language
English
Formats
Publication information
Publisher
Heidelberg: Springer
Subjects
More information
Scope and Contents
Contents
The 5HT(1A) receptor agonist sarizotan is in clinical development for the treatment of dyskinesia, a potentially disabling complication in Parkinson's disease. We investigated the effect of sarizotan on the clinical pharmacokinetics of probe drugs for cytochrome P450 (CYP) to evaluate the risk of CYP-related drug-drug interactions.
This was a do...
Alternative Titles
Full title
Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes : A combined cocktail trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_214482899
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_214482899
Other Identifiers
ISSN
0031-6970
E-ISSN
1432-1041
DOI
10.1007/s00228-006-0101-7
